GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.63 -0.40 (-0.85%)

Delayed Quote Updated: 2:42 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

45 46 Next >

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗

June 03, 2024

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...

Via Benzinga

Topics Lawsuit

GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 03, 2024

Via Benzinga

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

June 03, 2024

From GSK plc

Via Business Wire

Is Moderna Stock a Buy Now That It's a 2-Product Company? ↗

June 03, 2024

The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.

Via The Motley Fool

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

June 03, 2024

Via Benzinga

Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

June 02, 2024

From GSK plc

Via Business Wire

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK ↗

May 31, 2024

Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years.

Via Investor's Business Daily

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report ↗

May 27, 2024

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

Via Benzinga

Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit ↗

May 24, 2024

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.

Via Benzinga

Topics Lawsuit

First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential ↗

May 22, 2024

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.

Via Benzinga

GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims ↗

May 21, 2024

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,...

Via Benzinga

Topics Lawsuit Whistleblower

GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows ↗

May 21, 2024

GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.

Via Benzinga

GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale ↗

May 17, 2024

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.

Via Benzinga

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗

May 16, 2024

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...

Via Benzinga

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗

May 16, 2024

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

Via InvestorPlace

Topics Intellectual Property

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗

May 14, 2024

These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.

Via InvestorPlace

Amazon Pours ~$1.3B Investment Into French Operations: Report ↗

May 13, 2024

Amazon's €1.2 billion investment marks a significant stride in bolstering its French presence, promising 3,000 new jobs. The move aligns with France's push for tech investment, showcased at the 'Choose...

Via Benzinga

Topics Artificial Intelligence

FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It ↗

May 10, 2024

FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.

Via Benzinga

Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine ↗

May 10, 2024

The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says.

Via Investor's Business Daily

Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗

May 09, 2024

Via Benzinga

Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac ↗

May 08, 2024

Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.

Via Benzinga

Topics Lawsuit

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout? ↗

May 02, 2024

Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat?

Via Investor's Business Daily

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024 ↗

May 01, 2024

While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.

Via InvestorPlace

GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook ↗

May 01, 2024

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix....

Via Benzinga

Forget the Fed. These 3 Stocks Will Soar No Matter What ↗

April 29, 2024

The Fed's actions will have little impact on some stocks. Here are three excellent stocks that are likely to be unaffected by the Fed.

Via InvestorPlace

Topics Economy

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗

April 26, 2024

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...

Via Benzinga

Topics Intellectual Property Lawsuit

Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally ↗

May 01, 2024

A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)

Via Benzinga

Topics Economy

What's Going On With Pfizer Stock On Thursday? ↗

April 25, 2024

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.

Via Benzinga

Topics Intellectual Property

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.